At a glance
- SS-31 is the research name for elamipretide, a mitochondria-targeting tetrapeptide that associates with cardiolipin in the inner mitochondrial membrane. It is studied for effects on membrane organization, electron transport, and mitochondrial stress.
- The FDA granted accelerated approval to Forzinity (elamipretide) in September 2025 for eligible patients with Barth syndrome. That approval is narrow and product-specific; this SS-31 research vial is not Forzinity and is not clinically equivalent.
- Measure mitochondrial respiration, membrane potential, reactive-species production, and cell viability as separate endpoints.
- Use cardiolipin-deficient or mitochondrial-stress models when the question concerns the proposed membrane interaction.
What SS-31 is—and what the name does not establish
SS-31 is the research name for elamipretide, a mitochondria-targeting tetrapeptide that associates with cardiolipin in the inner mitochondrial membrane. It is studied for effects on membrane organization, electron transport, and mitochondrial stress.
Cardiolipin helps organize proteins that produce cellular energy. Elamipretide is proposed to stabilize cardiolipin-protein interactions and reduce inefficient electron transfer under stress. In plain language, it targets the membrane machinery around energy production rather than acting as a general antioxidant sponge.
Questions to settle before interpreting a result
A useful SS-31 study begins with material identity, a defined model, a relevant comparator, and an endpoint chosen before the result is known. Broad catalogue language cannot replace those controls.
- Measure mitochondrial respiration, membrane potential, reactive-species production, and cell viability as separate endpoints.
- Use cardiolipin-deficient or mitochondrial-stress models when the question concerns the proposed membrane interaction.
- Keep evidence for approved Forzinity in Barth syndrome separate from research claims in ageing, kidney, muscle, or cardiovascular models.
How to read the SS-31 evidence
These evidence snapshots summarize the most important distinctions in the published record. They do not combine unlike models or turn an experimental signal into a human-use claim.
Regulatory status · current
- Design
- One elamipretide product has accelerated approval
- Finding
- Forzinity is approved in the United States for a specific Barth-syndrome population under accelerated approval. Continued approval can depend on verification of clinical benefit; the label defines the actual product and indication.
- Read with care
- Keep the finding attached to the linked study’s exact material, design, population, exposure, and endpoint.
Mechanistic evidence
- Design
- Cardiolipin is the central research target
- Finding
- Biophysical and preclinical studies support interaction with inner-membrane cardiolipin and downstream effects on mitochondrial organization. Results vary with disease model and endpoint.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What not to assume
- Design
- Approval does not turn every SS-31 vial into Forzinity
- Finding
- The regulated product has defined formulation, potency, manufacturing, dose, and labelling. The shared active name does not establish pharmaceutical equivalence for research material.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What the evidence does not establish
The FDA granted accelerated approval to Forzinity (elamipretide) in September 2025 for eligible patients with Barth syndrome. That approval is narrow and product-specific; this SS-31 research vial is not Forzinity and is not clinically equivalent.
Mechanism, cell, animal, observational, and controlled human evidence answer different questions. A positive result at one level cannot be silently promoted to another, and evidence for a sponsor’s defined product does not establish equivalence for an independently sourced research material.
Keep the publication and the vial separate
A published paper identifies its own sequence or chemical identity, formulation, manufacturing context, analytical controls, exposure, and test system. Matching a familiar name on a label is not enough to show that a catalogue vial is the same study material.
For practical research planning, verify the lot-specific identity and documentation, then write the model, comparator, endpoint, and stopping criteria before testing. This guide does not provide preparation, dosing, injection, or human-use instructions.
Sources
Links lead to the paper, official registry, regulator page, or product label used for this guide. Registry records describe protocols and status; they are not treated as positive results.
- the official FDA labelU.S. Food and Drug Administration · Linked record
Forzinity is approved in the United States for a specific Barth-syndrome population under accelerated approval. Continued approval can depend on verification of clinical benefit; the label defines the actual product and indication. The result remains tied to the exact study material, design, population, and endpoint.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
Official Canadian advisory explaining that a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Vote for SS-31
This compound is not currently stocked. Add it to your five-choice catalogue ballot.